Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ribupatide

KaiNETIC-2

Fujian Shengdi Pharmaceutical Co · Phase 3 · Active, not recruiting · Enrollment 1270

NCT07284901

ArmPopulationDoseWeeksEstimandWeight change
Ribupatide: Dose 1Obesity + T2Dn/rn/rn/rn/r
Ribupatide: Dose 2Obesity + T2Dn/rn/rn/rn/r
Ribupatide: Dose 3Obesity + T2Dn/rn/rn/rn/r
Ribupatide: Dose 4Obesity + T2Dn/rn/rn/rn/r
PlaceboObesity + T2Dn/rn/rn/rn/r